Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma

British Journal of Cancer

Volumn 101, Issue 7, 2009, Pages 1175-1182

  Vasudev, N S ^a   Sim, S ^a   Cairns, D A ^a   Ferguson, R E ^a   Craven, R A ^a   Stanley, A ^a   Cartledge, J ^a   Thompson, D ^a   Selby, P J ^a   Banks, R E ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Biomarker; Cathepsin D; Prognosis; Proteomics; Renal cell carcinoma; Urine

Indexed keywords

CATHEPSIN D;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOASSAY; KIDNEY CARCINOMA; KIDNEY CELL; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CATHEPSIN D; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PILOT PROJECTS; PROGNOSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 70349694129     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605250     Document Type: Article

References (30)

1. Al Aynati M, Chen V, Salama S, Shuhaibar H, Treleaven D, Vincic L (2003) Interobserver and intraobserver variability using the Fuhrman grading system for renal cell carcinoma. Arch Pathol Lab Med 127: 593-596 (Pubitemid 36534945)
2. Barratt J, Topham P (2007) Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ 177: 361-368 (Pubitemid 47339533)
3. Bendtsen JD, Jensen LJ, Blom N, von Heijne G, Brunak S (2004a) Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng Des Sel 17: 349-356 (Pubitemid 39093515)
4. Bendtsen JD, Nielsen H, von Heijne G, Brunak S (2004b) Improved prediction of signal peptides: SignalP 3.0. J Mol Biol 340: 783-795 (Pubitemid 38829638)
5. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC (2003) Toward complete and accurate reporting of studies of diagnostic accuracy. The STARD initiative. Am J Clin Pathol 119: 18-22 (Pubitemid 37047892)
6. Capony F, Rougeot C, Montcourrier P, Cavailles V, Salazar G, Rochefort H (1989) Increased secretion, altered processing, and glycosylation of procathepsin D in human mammary cancer cells. Cancer Res 49: 3904-3909 (Pubitemid 19197419)
7. Craven RA, Hanrahan S, Totty N, Harnden P, Stanley AJ, Maher ER, Harris AL, Trimble WS, Selby PJ, Banks RE (2006a) Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma. Proteomics 6: 3880-3893 (Pubitemid 44065165)
8. Craven RA, Stanley AJ, Hanrahan S, Dods J, Unwin R, Totty N, Harnden P, Eardley I, Selby PJ, Banks RE (2006b) Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics 6: 2853-2864 (Pubitemid 43752045)
9. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592 (Pubitemid 46359643)
10. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C (2008) Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34: 193-205
11. Hanash SM, Pitteri SJ, Faca V (2008) Mining the plasma proteome for cancer biomarkers. Nature 452: 571-579
12. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast Jr RC (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312 (Pubitemid 350232263)
13. Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56: 337-344 (Pubitemid 30422619)
14. Karakiewicz PI, Suardi N, Capitanio U, Jeldres C, Ficarra V, Cindolo L, De La TA, Tostain J, Mulders PF, Bensalah K, Artibani W, Salomon L, Zigeuner R, Valeri A, Descotes JL, Rambeaud JJ, Mejean A, Montorsi F, Bertini R, Patard JJ (2009) A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 55: 287-295
15. Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS (2008) Proteomic contributions to personalized cancer care. Mol Cell Proteomics 7: 1780-1794
16. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97: 1663-1671 (Pubitemid 36350710)
17. Liaudet-Coopman E, Beaujouin M, Derocq D, Garcia M, Glondu-Lassis M, Laurent-Matha V, Prebois C, Rochefort H, Vignon F (2006) Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett 237: 167-179 (Pubitemid 43777078)
18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391 (Pubitemid 43080010)
19. Merseburger AS, Hennenlotter J, Simon P, Ohneseit PA, Kuehs U, Kruck S, Koch E, Vogel U, Stenzl A, Kuczyk MA (2005) Cathepsin D expression in renal cell cancer-clinical implications. Eur Urol 48: 519-526 (Pubitemid 41188415)
20. Merseburger AS, Hennenlotter J, Stenzl A, Beger G, Rinnab L, Kuczyk MA, Kuefer R (2007) Cathepsin D serum levels are not a valid serum marker in renal cell carcinoma. Urol Int 79: 41-43 (Pubitemid 47051817)
21. Obuchowski NA (2000) Sample size tables for receiver operating characteristic studies. AJR Am J Roentgenol 175: 603-608
22. Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, Kattan MW (2008) Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol 179: 2146-2151
23. Schachter LR, Cookson MS, Chang SS, Smith Jr JA, Dietrich MS, Jayaram G, Herrell SD (2007) Second prize: frequency of benign renal cortical tumors and histologic subtypes based on size in a contemporary series: what to tell our patients. J Endourol 21: 819-823 (Pubitemid 47443652)
24. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, McKiernan J, Russo P (2005) A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173: 48-51 (Pubitemid 39627669)
25. Vashishta A, Ohri SS, Proctor M, Fusek M, Vetvicka V (2006) Role of activation peptide of procathepsin D in proliferation and invasion of lung cancer cells. Anticancer Res 26: 4163-4170 (Pubitemid 46031486)
26. Vasudev NS, Ferguson RE, Cairns DA, Stanley AJ, Selby PJ, Banks RE (2008) Serum biomarker discovery in renal cancer using 2D-E and prefractionation by immunodepletion and isoelectric focusing: increasing coverage or more of the same? Proteomics 8: 5074-5085
27. Vetvicka V, Vetvickova J, Fusek M (2000) Role of procathepsin D activation peptide in prostate cancer growth. Prostate 44: 1-7 (Pubitemid 30390059)
28. Xue H, Lu B, Lai M (2008) The cancer secretome: a reservoir of biomarkers. J Transl Med 6: 52
29. Yan JX, Wait R, Berkelman T, Harry RA, Westbrook JA, Wheeler CH, Dunn MJ (2000) A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. Electrophoresis 21: 3666-3672
30. Zuhlsdorf M, Imort M, Hasilik A, von Figura K (1983) Molecular forms of beta-hexosaminidase and cathepsin D in serum and urine of healthy subjects and patients with elevated activity of lysosomal enzymes. Biochem J 213: 733-740